|
WO2021081395A1
|
|
Methods for treating patients having cfh mutations with recombinant cfh proteins
|
|
WO2021081401A1
|
|
Methods for treating patients having cfh mutations with cfh-encoding vectors
|
|
WO2021081348A1
|
|
Methods for treating patients having cfi mutations with recombinant cfi proteins
|
|
WO2021011903A1
|
|
Factor h potentiating antibodies and uses thereof
|
|
US2020291427A1
|
|
Crispr-based therapeutics for targeting htra1 and methods of use
|
|
US2020270614A1
|
|
RNAi-BASED THERAPEUTICS FOR TARGETING HTRA1 AND METHODS OF USE
|
|
WO2020102680A1
|
|
Antibody-based therapeutics for targeting htra1 and methods of use
|
|
US2020325481A1
|
|
Antisense-based therapeutics for targeting htra1 and methods of use
|
|
WO2020086735A1
|
|
Compositions and methods for treating age-related macular degeneration and other diseases
|
|
CN111788311A
|
|
Compositions and methods for treating age-related macular degeneration
|
